Gillian Housman
Family Medicine · Merriam, KSNPI 1891037693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 30.4% of the total. Reporting peaked in 2020 at $846 and has fallen 97.7% since, to $19 in 2024.
Across 127 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$558
- Novo Nordisk$192
- Lilly USA, LLC$181
- Amgen$169
- Boehringer Ingelheim$129
- AstraZeneca$105
- plus $502 from 21 others
What the payments were for
- Food & beverage$1,836100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $558 |
| Novo Nordisk | 13 | $192 |
| Lilly USA, LLC | 14 | $181 |
| Amgen | 11 | $169 |
| Boehringer Ingelheim | 9 | $129 |
| AstraZeneca | 8 | $105 |
| Amarin Pharma, Inc. | 5 | $77 |
| Pfizer | 4 | $53 |
| Merck | 4 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Ironwood Pharmaceuticals, Inc | 2 | $31 |
| Novartis | 2 | $25 |
| Eisai Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Boston Scientific | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| GSK | 1 | $12 |
| Nabriva Therapeutics, PLC | 1 | $11 |
How this compares
$1,836 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Merriam
- Nicholas GatzMerriam$13K
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Kyle PlatzManhattan$51K
- Eric AspinwallKansas City$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.